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Multiple myeloma (MM) is an haematological malignancy for which there is no cure 
with standard therapy (Howlader, et al 2014). Black patients have an incidence of MM that is 
twice that of white patients (Avet-Loiseau, et al 2010, Jagannath, et al 2007, Pineda-Roman, et 
al 2008, Sagaster, et al 2007). Despite the increased incidence, black patients with MM 
experience better overall survival (Howlader, et al 2014).   Cytogenetics represent an important 
factor in MM prognostication (Corre and Avet-Loiseau 2011).  Deletion of chromosome 13q, 
detected by routine karyotype analysis, or t(4; 14), detected by fluorescent in situ hybridization 
(FISH), have been associated with poorer treatment response rates and thus poorer prognosis 
(Avet-Loiseau, et al 2010, Jagannath, et al 2007, Pineda-Roman, et al 2008, Sagaster, et al 
2007).  Newer MM treatments, such as bortezomib and lenalidomide, appear to be effective in 
patients with high and low risk cytogenetics (Barlogie, et al 2008, Reece, et al 2009).  Despite 
efficacy in both cytogenetic profiles, survival improvements associated with bortezomib and 
lenalidomide may disproportionately benefit white patients, suggesting race-based cytogenetic 
differences (Kumar, et al 2008).  Little is known about how racial differences in cytogenetics 
may influence MM prognosis.   
To identify racial differences in common MM-associated chromosomal abnormalities, we 
examined routine cytogenetic results in a retrospective cohort study of patients from the United 
States Veterans Health administration (VHA). A cohort of 5,202 patients diagnosed with MM 
between 1 October  1998 and 31 December  2009 was identified using the VHA central cancer 
registry.  Patients were identified with International Classification of Diseases for Oncology, 3rd 
Edition (ICD-O-3) codes 9732/3, 9731/3 and 9734/3 (MM and plasmacytoma).  Among these 
patients, we identified a sub-cohort of 1,256 patients who had common procedural terminology 
(CPT) codes 88271-8275, 88291, 88299, 88365, 83896, 88237, 88261-88264, 88280, 88283 and 
88285, indicating that routine cytogenetic testing had been performed.  Further examination of 
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Fifteen patients from racial groups other than black or white were excluded, leading to a final 
cohort of 813 patients; of whom 228 were black and 585 were white (Fig 1).  
Additional data regarding date of birth, date of diagnosis, date of death, comorbidities, 
weight and height at time of diagnosis were obtained from VHA administrative datasets. The 
Romano comorbidity index was calculated using International Classification of Disease (ICD)-9 
codes (Romano et al, 1993). Body Mass Index was calculated using weight and height at time of 
diagnosis using the standard formula: weight in kilograms divided by height in metres squared.  
Chi-Square test and Fisher’s exact test was used to assess for race-based differences in 
the following cytogenetic abnormalities: del(13q), hypodiploidy, hyperdiploidy and 
translocations involving the immunoglobulin heavy-chain (chromosome 14). Cox Proportional 
Hazard model was used to estimate association between race and survival while adjusting for 
age. A two-tailed α significance level of 0.05 was considered statistically significant.  All 
statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). 
Among the 813 patients, normal cytogenetic profiles, isolated Y chromosome deletion, or 
no mitotic activity were observed in 704 (87%). Only four chromosome 14 translocations were 
observed on routine cytogenetics; no statistical conclusions could be drawn.  Hyperdiploidy was 
noted in 13/228 (5.7%) black and 45/585 (7.7%) white patients (p=0.32). Del(13q) was detected 
in 8/228 (3.5%) black patients and 21/585 (3.6%) white patients (p=0.96). Hypodiploidy was 
noted in 4/228 (1.8%) black and 12/585 (2.0%) white patients (p=1.00). There was no difference 
in age-adjusted survival based on race (Hazard ratio [HR], 0.90; 95% confidence interval [CI] 
0.72-1.14). Consistent with other studies, black patients in this cohort were significantly younger 
than white patients (mean age 62.2 vs. 66.6 , respectively, p<0.0001)  (Howlader, et al 2014).  
Despite having a younger mean age, black patients in our cohort had a significantly higher mean 
Charlson score than white patients (Table I).   
This is the largest investigation of racial disparities in MM cytogenetics to date.  Contrary 
to our a priori hypothesis, we did not find a significant difference in metaphase cytogenetics 
between black and white patients. While previously published papers (Corre and Avet-Loiseau 
2011, Howlader, et al 2014, Kumar, et al 2008) alluded to a better prognosis for black patients, 
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According to the literature, hyperdiploidy and del(13q) have the highest rates of abnormal 
karyotype detection, which our data supports;  however, at a lower frequency than previously 
observed (Corre and Avet-Loiseau 2011).  Despite their younger age, black patients had a higher 
mean co-morbidity score, which would increase the risk of death due to causes other than MM.   
The strengths of this study include drawing data from the largest health system in the 
United States, providing the best available statistical power as well as detailed patient 
information.  A major limitation of this study was the lack of FISH results in most patients.  The 
low frequency of cytogenetic abnormalities is attributable to the historic use of routine 
cytogenetics instead of FISH testing in the VHA. Our study population was predominately m l , 
which is similar to national data (Howlader, et al 2014); as a consequence, these findings may 
not be generalizable to women.   
In conclusion, we found no significant racial differences in metaphase cytogenetics 
among a large cohort of MM patients. Further research into how race might influence genetic 
differences in plasma cell malignancies will require comparison of FISH testing or genomic 
sequencing results.  Alternatively, it is possible that there are no major race-based differences in 
the malignant plasma cells and that those racial differences in MM incidence are driven by 
differences in environmental exposures or molecular abnormalities in tissues other than the 
malignant plasma cells.  
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Table I:  Basic Demographics of United States veterans with Multiple Myeloma with routine 
cytogenetic testing within the Veterans Health administration system, by race (n= 813) 
  
Race  
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N=813 (n=585)  (n=228) 
Age (mean years) 65.3 66.6 62.2 <0.0001† 
Male (%) 97.8 98.5 96.1 0.0360* 
Body mass index (%)   
     <18.5  1.1 0.9 1.8 
   18.5 - <25 23.7 22.6 26.8 
   25 - <30 36.3 35.9 37.3 
   ≥30 26.2 27.2 23.7 
   Unknown 12.7 13.5 10.5 0.1018§ 
Comorbidities (mean Charlson score) 2.8 2.6 3.1 0.0366† 
Diagnosis year (median) 2006 2006 2007 0.0466‡ 
* Chi-square test; † Anova test; § Cochran-Mantel-Haenszel (Row Mean Score) test; ‡ 
Wilcoxon Two-Sample Test 
 
 
Figure 1:  CONSORT Diagram 
MM, multiple myeloma; CPT, common procedural terminology 
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